Me either but I have worked at a fairly large broker and there I learnt there are many ways to make money. For example where I worked 70% of staff were Brokers (or related) but the majority of profits came from the Corporate section which was a single digit % of headcount. That department would run bookbuilds for CRs, IPOs, etc. The brokers were meant to be independent and work off research but the reality is that flogging a bad IPO so the shares go to customers who will lose money (over the long term) is a better outcome for them instead of needing to buy the shares themselves (underwriting).
UBS is known as a market marker (or a liquidity provider, which is a bit different) so it may be they have no finanical incentive on whether the stock goes up or down and they make their money in another way which is either controlling spread (commission), or acting orders on behalf of a client (which could be anything).
https://www.investopedia.com/ask/answers/06/brokerandmarketmaker.asp
- Forums
- ASX - By Stock
- NEU
- Ann: Update - Notification of buy-back - NEU
NEU
neuren pharmaceuticals limited
Add to My Watchlist
3.04%
!
$13.24

Ann: Update - Notification of buy-back - NEU, page-38
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$13.24 |
Change
0.390(3.04%) |
Mkt cap ! $1.652B |
Open | High | Low | Value | Volume |
$13.15 | $13.37 | $12.92 | $4.177M | 318.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 95 | $13.23 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.25 | 465 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
10 | 222 | 13.330 |
3 | 416 | 13.320 |
4 | 633 | 13.310 |
6 | 1357 | 13.300 |
8 | 1478 | 13.290 |
Price($) | Vol. | No. |
---|---|---|
13.350 | 278 | 5 |
13.360 | 2382 | 6 |
13.370 | 1428 | 5 |
13.380 | 1753 | 5 |
13.390 | 2281 | 6 |
Last trade - 12.03pm 18/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online